A Phase 3 interventional study of Lebrikizumab and Placebo in Asthma, sponsored by Hoffmann-La Roche. Completed at 181 sites in 26 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-17.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing lebrikizumab in Asthma — none open to participants now, none under way, none of them phase 3. lebrikizumab · Asthma.
Among the 12 studies testing lebrikizumab in Asthma, this one has the largest enrollment, is one of 3 that started in 2013, is one of 5 in phase 3, and was the 6th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →None of the 12 studies testing lebrikizumab in Asthma is open now. The open studies under Asthma, anywhere →
lebrikizumab: first FDA approval 2024 (EBGLYSS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 3 started in 2013.
This study's enrollment of 1,081 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 224 across the 12 interventional studies. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 2 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
41 studies in Asthma by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 39 finished, 16 (41%) have results posted.
Among the 41 studies in Asthma by Hoffmann-La Roche, this one is the 2nd largest by enrollment of the 35 interventional ones that give a count, is one of 5 that started in 2013, is one of 9 in phase 3, and was the 27th registered.
Hoffmann-La Roche’s Asthma studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing lebrikizumab in Asthma, from their registry updates:
Among Hoffmann-La Roche’s 41 in Asthma:
This tab as a report to print or save as PDF → With an account.
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab in participants with asthma whose disease remains uncontrolled despite daily treatment with inhaled corticosteroid (ICS) therapy and at least one second controller medication. Participants will be randomized in 1:1:1 ratio to receive double-blind treatment with either lebrikizumab ("high" or "low") or placebo, administered subcutaneously (SC) every 4 weeks for 52 weeks, in addition to their standard-of-care therapy. This will be followed by a 52-week double-blind active treatment extension. During double-blind active treatment extension period, all participants will receive SC injection of lebrikizumab from Week 53 to Week 104. The anticipated time on study treatment is 104 weeks. After study treatment, all participants will complete a 20-week safety follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive SC injection of lebrikizumab (125 milligrams \[mg\]) every 4 weeks for 104 weeks.
Drug: Lebrikizumab
Participants will receive SC injection of lebrikizumab (37.5 mg) every 4 weeks for 104 weeks.
Drug: Lebrikizumab · Drug: Placebo
Participants will receive SC injection of lebrikizumab matching placebo every 4 weeks for 52 weeks during placebo-controlled period and then SC injection of lebrikizumab at 125 or 37.5 mg for 52 weeks during active treatment extension period.
Drug: Lebrikizumab · Drug: Placebo
Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.
Also known as: RO5490255
Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.
Adjusted Exacerbation Rate of Asthma During the 52-Week PCP
Asthma exacerbation is defined as new or increased asthma symptoms (i.e., wheeze, cough, dyspnea, chest tightness, and/or night-time awakening due to these symptoms) that lead to systemic corticosteroid (CS) treatment (oral, intravenous (IV), or intramuscular (IM) CS for ≥ 3 days or an emergency department visit with at least one dose of IV or IM CS) or to hospitalization. Results are reported as a 'Number' representing the model-adjusted incidence rate of asthma exacerbations per person-year. To account for early discontinuation, for each patient, the time at risk (in years) was computed as the duration of this time period (last day minus first day \[in days\] plus 1) divided by 365.25. The 'first day' was the day of randomization to the PCP. For patients entering the ATE, the 'last day' was the day prior to ATE randomization. For patients not entering the ATE, the 'last day' was at the last study visit on/prior to Study Day 379 (365 days plus a 14-day window).
Time frame: Baseline up to 52 weeks
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 52
FEV1 is the maximal amount of air, which can be forcefully exhaled in one second. Measurements were performed before use of bronchodilator. Reported is the absolute change from baseline in FEV1 to the end of the placebo-controlled period at Week 52.
Time frame: Week 52
Time to First Asthma Exacerbation During the 52-week PCP
An asthma exacerbation is defined as new or increased asthma symptoms (including wheeze, cough, dyspnea, chest tightness, and/or night-time awakening due to these symptoms) that lead to treatment with systemic corticosteroids or to hospitalisation. Treatment with systemic corticosteroids is defined as treatment with oral, intravenous (IV), or intramuscular (IM) corticosteroids for at least 3 days or an emergency department visit with at least one dose of IV or IM corticosteroids. Reported is the time to first asthma exacerbation during the 52-week placebo-controlled period.
Time frame: Baseline up to 52 weeks
Rate of Urgent Asthma-Related Health Care Utilization (HCU) During the 52-week PCP
Urgent health care utilization was defined as hospitalizations, emergency department visits, and acute care visits. Results are reported as a 'Number' representing the model-adjusted incidence rate of urgent asthma-related HCU events per person-year. To account for early discontinuation, for each patient, the time at risk (in years) was computed as the duration of this time period (last day minus first day \[in days\] plus 1) divided by 365.25. The 'first day' was the day of randomization to the PCP. For patients entering the ATE, the 'last day' was the day prior to ATE randomization. For patients not entering the ATE, the 'last day' was at the last study visit on/prior to Study Day 379 (365 days plus a 14-day window).
Time frame: Baseline up to Week 52
Absolute Change From Baseline in Standardized AQLQ Score at Week 52
Asthma-specific health-related quality of life was assessed by the overall score of the Standardized AQLQ. The AQLQ is a self-administered test with 32 questions; each with seven possible answers ranging from 1 to 7 with a higher score being more favorable. Total score is calculated as follows: sum of items 1to 32 divided by 32 for a score range of 1 to 7 with a higher score indicating a better outcome. Reported is the change in AQLQ score from baseline to the end of the placebo-controlled period at Week 52.
Time frame: Week 52
Absolute Change From Baseline In Asthma Rescue Medication Use at Week 52
Reported here is the change in the number of puffs or nebulized treatments of asthma rescue medication from baseline to the end of the PCP at Week 52.
Time frame: Week 52
Absolute Change From Baseline in ACQ-5 Score at Week 52
The ACQ-5 is test with 5 questions; each with seven possible answers ranging from 0 to 6 with a lower score being more favorable. Total score range is 0 to 30 with a lower score indicating a better outcome. Reported is the change in ACQ-5 score from baseline to the end of the PCP at Week 52.
Time frame: Baseline, Week 52
Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Lebrikizumab
The safety population included all participants who received at least one dose of study medication.
Time frame: Baseline up to Week 124 (assessed at Baseline, Weeks 4, 12, 24, 36, 52 and safety follow-up [20 weeks] or end of study)
Percentage of Participants With Adverse Events (AEs)
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. The safety population included all participants who received at least one dose of study medication.
Time frame: Baseline up to Week 52 for Placebo arm. Week 53 to Week 104 for PBO/Lebrikizumab crossover arms. Baseline up to Week 104 for Lebrikizumab-only arms.
Minimum Serum Concentration (Cmin) of Lebrikizumab
Time frame: Predose (0 hour) at Weeks 4, 12, 24, 36, and 52
Participants with asthma, whose disease remained uncontrolled despite daily treatment with inhaled corticosteroid (ICS) therapy and at least one second controller medication, were recruited in 26 countries.
| Milestone | Placebo | Lebrikizumab (37.5 mg) | Lebrikizumab (125 mg) | Placebo/Lebrikizumab (37.5 mg) | Placebo/Lebrikizumab (125 mg) |
|---|---|---|---|---|---|
| Started | 362 | 360 | 359 | 0 | 0 |
| Completed | 326 | 336 | 335 | 0 | 0 |
| Not completed | 36 | 24 | 24 | 0 | 0 |
| Withdrew: Withdrawal by subject | 19 | 14 | 13 | 0 | 0 |
| Withdrew: Adverse event | 6 | 5 | 5 | 0 | 0 |
| Withdrew: Lost to follow-up | 4 | 0 | 2 | 0 | 0 |
| Withdrew: Physician decision | 2 | 3 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 2 | 1 | 1 | 0 | 0 |
| Withdrew: Other | 1 | 0 | 2 | 0 | 0 |
| Withdrew: Non-compliance | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | Lebrikizumab (37.5 mg) | Lebrikizumab (125 mg) | Placebo/Lebrikizumab (37.5 mg) | Placebo/Lebrikizumab (125 mg) |
|---|---|---|---|---|---|
| Started | 0 | 336 | 335 | 159 | 157 |
| Completed | 0 | 302 | 285 | 139 | 139 |
| Not completed | 0 | 34 | 50 | 20 | 18 |
| Withdrew: Withdrawal by subject | 0 | 20 | 43 | 13 | 15 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 6 | 2 | 2 | 1 |
| Withdrew: Other | 0 | 6 | 0 | 2 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Non-compliance | 0 | 0 | 3 | 2 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 1 | 0 | 0 |
Asthma exacerbation is defined as new or increased asthma symptoms (i.e., wheeze, cough, dyspnea, chest tightness, and/or night-time awakening due to these symptoms) that lead to systemic corticosteroid (CS) treatment (oral, intravenous (IV), or intramuscular (IM) CS for ≥ 3 days or an emergency department visit with at least one dose of IV or IM CS) or to hospitalization. Results are reported as a 'Number' representing the model-adjusted incidence rate of asthma exacerbations per person-year. To account for early discontinuation, for each patient, the time at risk (in years) was computed as the duration of this time period (last day minus first day \[in days\] plus 1) divided by 365.25. The 'first day' was the day of randomization to the PCP. For patients entering the ATE, the 'last day' was the day prior to ATE randomization. For patients not entering the ATE, the 'last day' was at the last study visit on/prior to Study Day 379 (365 days plus a 14-day window).
| Asthma exacerbations per person-year | Biomarker-High: Placebo | Biomarker-High: Lebrikizumab 37.5 mg | Biomarker-High: Lebrikizumab 125 mg | Biomarker-Low: Placebo | Biomarker-Low: Lebrikizumab 37.5 mg | Biomarker-Low: Lebrikizumab 125 mg |
|---|---|---|---|---|---|---|
| Adjusted Exacerbation Rate of Asthma During the 52-Week PCP | 0.95 | 0.46 | 0.66 | 0.60 | 0.33 | 0.44 |
FEV1 is the maximal amount of air, which can be forcefully exhaled in one second. Measurements were performed before use of bronchodilator. Reported is the absolute change from baseline in FEV1 to the end of the placebo-controlled period at Week 52.
| millilitre (mL) | Biomarker-High: Placebo | Biomarker-High: Lebrikizumab 37.5 mg | Biomarker-High: Lebrikizumab 125 mg | Biomarker-Low: Placebo | Biomarker-Low: Lebrikizumab 37.5 mg | Biomarker-Low: Lebrikizumab 125 mg |
|---|---|---|---|---|---|---|
| Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 52 | 98 ± 25 | 201 ± 25 | 211 ± 25 | 25 ± 33 | 38 ± 32 | 150 ± 33 |
An asthma exacerbation is defined as new or increased asthma symptoms (including wheeze, cough, dyspnea, chest tightness, and/or night-time awakening due to these symptoms) that lead to treatment with systemic corticosteroids or to hospitalisation. Treatment with systemic corticosteroids is defined as treatment with oral, intravenous (IV), or intramuscular (IM) corticosteroids for at least 3 days or an emergency department visit with at least one dose of IV or IM corticosteroids. Reported is the time to first asthma exacerbation during the 52-week placebo-controlled period.
| Weeks | Biomarker-High: Placebo | Biomarker-High: Lebrikizumab 37.5 mg | Biomarker-High: Lebrikizumab 125 mg | Biomarker-Low: Placebo | Biomarker-Low: Lebrikizumab 37.5 mg | Biomarker-Low: Lebrikizumab 125 mg |
|---|---|---|---|---|---|---|
| Time to First Asthma Exacerbation During the 52-week PCP | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Urgent health care utilization was defined as hospitalizations, emergency department visits, and acute care visits. Results are reported as a 'Number' representing the model-adjusted incidence rate of urgent asthma-related HCU events per person-year. To account for early discontinuation, for each patient, the time at risk (in years) was computed as the duration of this time period (last day minus first day \[in days\] plus 1) divided by 365.25. The 'first day' was the day of randomization to the PCP. For patients entering the ATE, the 'last day' was the day prior to ATE randomization. For patients not entering the ATE, the 'last day' was at the last study visit on/prior to Study Day 379 (365 days plus a 14-day window).
| HCU Events per person-year | Biomarker-High: Placebo | Biomarker-High: Lebrikizumab 37.5 mg | Biomarker-High: Lebrikizumab 125 mg | Biomarker-Low: Placebo | Biomarker-Low: Lebrikizumab 37.5 mg | Biomarker-Low: Lebrikizumab 125 mg |
|---|---|---|---|---|---|---|
| Rate of Urgent Asthma-Related Health Care Utilization (HCU) During the 52-week PCP | 0.58 | 0.24 | 0.62 | 0.29 | 0.41 | 0.20 |
Asthma-specific health-related quality of life was assessed by the overall score of the Standardized AQLQ. The AQLQ is a self-administered test with 32 questions; each with seven possible answers ranging from 1 to 7 with a higher score being more favorable. Total score is calculated as follows: sum of items 1to 32 divided by 32 for a score range of 1 to 7 with a higher score indicating a better outcome. Reported is the change in AQLQ score from baseline to the end of the placebo-controlled period at Week 52.
| Score on scale | Biomarker-High: Placebo | Biomarker-High: Lebrikizumab 37.5 mg | Biomarker-High: Lebrikizumab 125 mg | Biomarker-Low: Placebo | Biomarker-Low: Lebrikizumab 37.5 mg | Biomarker-Low: Lebrikizumab 125 mg |
|---|---|---|---|---|---|---|
| Absolute Change From Baseline in Standardized AQLQ Score at Week 52 | 0.78 ± 0.064 | 0.93 ± 0.064 | 0.91 ± 0.064 | 0.85 ± 0.098 | 0.73 ± 0.096 | 0.86 ± 0.097 |
Reported here is the change in the number of puffs or nebulized treatments of asthma rescue medication from baseline to the end of the PCP at Week 52.
| Puffs per day | Biomarker-High: Placebo | Biomarker-High: Lebrikizumab 37.5 mg | Biomarker-High: Lebrikizumab 125 mg | Biomarker-Low: Placebo | Biomarker-Low: Lebrikizumab 37.5 mg | Biomarker-Low: Lebrikizumab 125 mg |
|---|---|---|---|---|---|---|
| Absolute Change From Baseline In Asthma Rescue Medication Use at Week 52 | -0.6 ± 0.1 | -1.1 ± 0.1 | -1.1 ± 0.1 | -0.8 ± 0.2 | -0.8 ± 0.2 | -1.2 ± 0.2 |
The ACQ-5 is test with 5 questions; each with seven possible answers ranging from 0 to 6 with a lower score being more favorable. Total score range is 0 to 30 with a lower score indicating a better outcome. Reported is the change in ACQ-5 score from baseline to the end of the PCP at Week 52.
| Score on scale | Biomarker-High: Placebo | Biomarker-High: Lebrikizumab 37.5 mg | Biomarker-High: Lebrikizumab 125 mg | Biomarker-Low: Placebo | Biomarker-Low: Lebrikizumab 37.5 mg | Biomarker-Low: Lebrikizumab 125 mg |
|---|---|---|---|---|---|---|
| Absolute Change From Baseline in ACQ-5 Score at Week 52 | -0.8 ± 0.07 | -0.9 ± 0.06 | -0.9 ± 0.07 | -0.8 ± 0.09 | -0.8 ± 0.09 | -0.8 ± 0.09 |
The safety population included all participants who received at least one dose of study medication.
| Percentage of Participants | Placebo | Placebo/Lebrikizumab (37.5 mg) | Placebo/Lebrikizumab (125 mg) | Lebrikizumab (37.5 mg) | Lebrikizumab (125 mg) |
|---|---|---|---|---|---|
| Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Lebrikizumab | 0 | 11.3 | 10.8 | 18.7 | 15.1 |
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. The safety population included all participants who received at least one dose of study medication.
| Percentage of Participants | Placebo | Placebo/Lebrikizumab (37.5 mg) | Placebo/Lebrikizumab (125 mg) | Lebrikizumab (37.5 mg) | Lebrikizumab (125 mg) |
|---|---|---|---|---|---|
| Percentage of Participants With Adverse Events (AEs) | 82.3 | 78.0 | 77.7 | 93.1 | 90.0 |
| microgram per millilitre (μg/mL) | Lebrikizumab (37.5 mg) | Lebrikizumab (125 mg) |
|---|---|---|
| Week 4: (n= 351, 351) | 2.40 ± 1.67 | 8.47 ± 3.61 |
| Week 12: (n= 352, 345) | 3.78 ± 2.21 | 14.1 ± 6.17 |
| Week 24: (n=340, 336) | 4.38 ± 2.28 | 16.4 ± 7.78 |
| Week 36: (n=335, 329) | 4.87 ± 3.12 | 16.7 ± 7.62 |
| Week 52: (n= 328, 318) | 4.66 ± 2.94 | 16.9 ± 8.28 |
Collected over For the Placebo arm, the data collection period was up to 52 weeks (PCP; Weeks 1-52). For the Placebo/Lebrikizumab 37.5 mg and Placebo/Lebrikizumab 125 mg crossover arms, the data collection period was up to 52 weeks (ATE; Weeks 53-104). For the continuous Lebrikizumab 37.5 mg and Lebrikizumab 125 mg arms, the data collection period was up to 104 weeks (PCP and ATE).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 1/362 (0.3%) | 32/362 (8.8%) | 240/362 (66.3%) |
| Placebo/Lebrikizumab (37.5 mg) | 0/159 (0%) | 14/159 (8.8%) | 92/159 (57.9%) |
| Placebo/Lebrikizumab (125 mg) | 0/157 (0%) | 16/157 (10.2%) | 96/157 (61.1%) |
| Lebrikizumab (37.5 mg) | 0/360 (0%) | 48/360 (13.3%) | 279/360 (77.5%) |
| Lebrikizumab (125 mg) | 0/359 (0%) | 49/359 (13.6%) | 282/359 (78.6%) |
| Event | Placebo | Placebo/Lebrikizumab (37.5 mg) | Placebo/Lebrikizumab (125 mg) | Lebrikizumab (37.5 mg) | Lebrikizumab (125 mg) |
|---|---|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 6/362 | 3/159 | 4/157 | 12/360 | 11/359 |
| PneumoniaInfections and infestations | 1/362 | 3/159 | 0/157 | 4/360 | 2/359 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/362 | 1/159 | 2/157 | 1/360 | 0/359 |
| CholelithiasisHepatobiliary disorders | 0/362 | 0/159 | 0/157 | 3/360 | 1/359 |
| CellulitisInfections and infestations | 3/362 | 0/159 | 0/157 | 0/360 | 0/359 |
| Atrial fibrillationCardiac disorders | 0/362 | 0/159 | 1/157 | 0/360 | 2/359 |
| PericarditisCardiac disorders | 0/362 | 0/159 | 1/157 | 0/360 | 1/359 |
| Epiploic appendagitisGastrointestinal disorders | 0/362 | 0/159 | 1/157 | 0/360 | 0/359 |
| PapillitisGeneral disorders | 0/362 | 0/159 | 1/157 | 0/360 | 0/359 |
| Respiratory tract infectionInfections and infestations | 1/362 | 0/159 | 1/157 | 1/360 | 0/359 |
| Event | Placebo | Placebo/Lebrikizumab (37.5 mg) | Placebo/Lebrikizumab (125 mg) | Lebrikizumab (37.5 mg) | Lebrikizumab (125 mg) |
|---|---|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 146/362 | 54/159 | 61/157 | 156/360 | 184/359 |
| NasopharyngitisInfections and infestations | 54/362 | 22/159 | 24/157 | 72/360 | 81/359 |
| Upper respiratory tract infectionInfections and infestations | 33/362 | 10/159 | 17/157 | 59/360 | 67/359 |
| BronchitisInfections and infestations | 25/362 | 12/159 | 12/157 | 60/360 | 48/359 |
| SinusitisInfections and infestations | 21/362 | 5/159 | 8/157 | 26/360 | 34/359 |
| HeadacheNervous system disorders | 28/362 | 9/159 | 5/157 | 34/360 | 29/359 |
| InfluenzaInfections and infestations | 6/362 | 6/159 | 1/157 | 28/360 | 21/359 |
| RhinitisInfections and infestations | 13/362 | 1/159 | 12/157 | 24/360 | 20/359 |
| Back painMusculoskeletal and connective tissue disorders | 14/362 | 4/159 | 5/157 | 22/360 | 24/359 |
| Rhinitis allergicRespiratory, thoracic and mediastinal disorders | 13/362 | 6/159 | 6/157 | 24/360 | 8/359 |
The ITT population presented includes two subgroups: biomarker-high (participants with serum periostin levels ≥ 50 ng/mL or blood eosinophil count ≥ 300 cells/μL at Visit 1) and biomarker-low (participants with serum periostin levels \< 50 ng/mL and blood eosinophil count \< 300 cells/μL at Visit 1).
| Age, Continuous(years) | Biomarker-High: Placebo | Biomarker-High: Lebrikizumab 37.5 mg | Biomarker-High: Lebrikizumab 125 mg | Biomarker-Low: Placebo | Biomarker-Low: Lebrikizumab 37.5 mg | Biomarker-Low: Lebrikizumab 125 mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 51.3 ± 12.4 | 51.3 ± 13.2 | 51.8 ± 12.6 | 51.2 ± 12.1 | 51.5 ± 12.1 | 49.0 ± 12.4 | 51.2 ± 12.6 |
| Sex: Female, Male(Participants) | Biomarker-High: Placebo | Biomarker-High: Lebrikizumab 37.5 mg | Biomarker-High: Lebrikizumab 125 mg | Biomarker-Low: Placebo | Biomarker-Low: Lebrikizumab 37.5 mg | Biomarker-Low: Lebrikizumab 125 mg | Total |
|---|---|---|---|---|---|---|---|
| Female | 166 | 162 | 178 | 65 | 72 | 70 | 713 |
| Male | 90 | 89 | 77 | 41 | 37 | 34 | 368 |
| Ethnicity (NIH/OMB)(Participants) | Biomarker-High: Placebo | Biomarker-High: Lebrikizumab 37.5 mg | Biomarker-High: Lebrikizumab 125 mg | Biomarker-Low: Placebo | Biomarker-Low: Lebrikizumab 37.5 mg | Biomarker-Low: Lebrikizumab 125 mg | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 28 | 32 | 38 | 12 | 11 | 11 | 132 |
| Not Hispanic or Latino | 228 | 219 | 217 | 94 | 98 | 93 | 949 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Biomarker-High: Placebo | Biomarker-High: Lebrikizumab 37.5 mg | Biomarker-High: Lebrikizumab 125 mg | Biomarker-Low: Placebo | Biomarker-Low: Lebrikizumab 37.5 mg | Biomarker-Low: Lebrikizumab 125 mg | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 2 | 1 | 0 | 0 | 0 | 5 |
| Asian | 40 | 33 | 34 | 1 | 6 | 6 | 120 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 1 | 0 | 2 |
| Black or African American | 20 | 12 | 7 | 9 | 7 | 8 | 63 |
| White | 191 | 197 | 209 | 95 | 94 | 86 | 872 |
| More than one race | 1 | 0 | 1 | 0 | 0 | 0 | 2 |
| Unknown or Not Reported | 2 | 7 | 2 | 1 | 1 | 4 | 17 |
| Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)(mL) | Biomarker-High: Placebo | Biomarker-High: Lebrikizumab 37.5 mg | Biomarker-High: Lebrikizumab 125 mg | Biomarker-Low: Placebo | Biomarker-Low: Lebrikizumab 37.5 mg | Biomarker-Low: Lebrikizumab 125 mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 1795 ± 572 | 1785 ± 541 | 1779 ± 588 | 1982 ± 624 | 1865 ± 509 | 1918 ± 517 | 1826 ± 566 |
| Standardized Asthma Quality of Life Questionnaire (AQLQ) Score(Score on scale) | Biomarker-High: Placebo | Biomarker-High: Lebrikizumab 37.5 mg | Biomarker-High: Lebrikizumab 125 mg | Biomarker-Low: Placebo | Biomarker-Low: Lebrikizumab 37.5 mg | Biomarker-Low: Lebrikizumab 125 mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 4.23 ± 1.04 | 4.15 ± 1.04 | 4.16 ± 1.04 | 4.06 ± 1.12 | 4.22 ± 1.17 | 4.23 ± 0.96 | 4.18 ± 1.05 |
| Asthma Control Questionnaire-5 (ACQ-5) Score(Score on scale) | Biomarker-High: Placebo | Biomarker-High: Lebrikizumab 37.5 mg | Biomarker-High: Lebrikizumab 125 mg | Biomarker-Low: Placebo | Biomarker-Low: Lebrikizumab 37.5 mg | Biomarker-Low: Lebrikizumab 125 mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 2.67 ± 0.72 | 2.62 ± 0.72 | 2.61 ± 0.74 | 2.73 ± 0.85 | 2.59 ± 0.75 | 2.56 ± 0.74 | 2.63 ± 0.74 |
| Baseline Use of inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA)(Participants) | Biomarker-High: Placebo | Biomarker-High: Lebrikizumab 37.5 mg | Biomarker-High: Lebrikizumab 125 mg | Biomarker-Low: Placebo | Biomarker-Low: Lebrikizumab 37.5 mg | Biomarker-Low: Lebrikizumab 125 mg | Total |
|---|---|---|---|---|---|---|---|
| ICS < 1000 µg/day or no LABA | 149 | 135 | 137 | 54 | 64 | 62 | 601 |
| ICS ≥ 1000 µg/day and LABA | 107 | 116 | 118 | 52 | 45 | 42 | 480 |
1 further baseline measures are reported on the registry.
Showing the first 100 of 181 sites across 26 countries. Choose a country and city above to see the rest.
Ran from Jul 2013 to primary completion in Dec 2016, 41 months.
Results were first posted in Jul 2026, 9 years 6 months after primary completion.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 41 months is above that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lebrikizumab